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Abstract
Objective—To report on the prevalence of psychiatric comorbidity and its association with 
illness severity in depressed HIV patients.
Methods—As part of a multi-site randomized controlled trial of depression treatment for HIV 
patients, 304 participants meeting criteria for current Major Depressive Disorder (MDD) were 
assessed for other mood, anxiety and substance use disorders with the Mini-International 
Neuropsychiatric Interview, a structured psychiatric diagnostic interview. We also assessed 
baseline adherence, risk, and health measures.
Results—Complicated depressive illness was common. Only 18% of participants experienced 
MDD with no comorbid psychiatric diagnoses; 49% had comorbid dysthymia, 62% had ≥1 
comorbid anxiety disorder, and 28% had a comorbid substance use disorder. Self-reported 
antiretroviral adherence did not differ by the presence of psychiatric comorbidity. However, 
psychiatric comorbidity was associated with worse physical health and functioning: compared to 
those with MDD alone, individuals with ≥1 comorbidity reported more HIV symptoms (5.1 vs. 
4.1, p-value=0.01), and worse mental health-related quality of life on the SF-12 (29 vs. 35, 
p<0.01).
Conclusion—For HIV patients with MDD, chronic depression and psychiatric comorbidity are 
strikingly common, and this complexity is associated with greater HIV disease severity and worse 
quality of life. Appreciating this comorbidity can help clinicians better target those at risk of 
harder-to-treat HIV disease, and underscores the challenge of treating depression in this 
population.
Keywords
depression; psychiatric comorbidity; quality of life
1.1 INTRODUCTION
Twenty to thirty percent of HIV-infected patients have depression or depressive symptoms, 
and these states have been associated with decreased access to antiretroviral therapy (ART) 
[1-4], decreased likelihood of initiation of and retention in HIV care,[5, 6] poor 
antiretroviral adherence,[7] worse psychiatric outcomes,[8] and worse medical outcomes, 
including lower likelihood of virologic suppression, faster HIV disease progression, and 
higher mortality rates.[9, 10] HIV care providers and researchers have argued that increased 
access to effective depression treatment would lead to substantial improvements in HIV 
clinical outcomes for affected individuals,[8, 11] although current evidence is somewhat 
mixed on this point.[12-18]
A key consideration in determining whether improved depression care can lead to improved 
HIV outcomes in HIV-infected individuals with Major Depressive Disorder (MDD) is how 
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comorbid psychiatric illness might confound this relationship. Indeed, few studies have 
thoroughly considered the role of psychiatric comorbidity, i.e., the co-occurrence of other 
psychiatric disorders with depression, in explaining the observed association between 
depressive symptoms and adverse HIV outcomes. For psychiatric illness in general, and 
MDD in particular, having more than one concurrent psychiatric diagnosis is common.[19] 
This psychiatric comorbidity is strongly related to both greater psychiatric severity [20] and 
worse psychiatric outcomes (including greater fatigue and functional impairment[21] and 
higher rates of suicide attempts[22]). In addition, psychiatric comorbidity is associated with 
greater medical symptomatology[23] and worse medical outcomes.[24] Finally, MDD that is 
comorbid with dysthymic, anxiety, or substance use disorders is likely to be more difficult to 
treat, which might complicate efforts to reduce depressive severity and improve HIV 
outcomes through depression treatment interventions.
However, documentation of psychiatric comorbidity in HIV patients receiving treatment in 
limited. Indeed, while studies have reported on the heavy burden of psychiatric illness in 
HIV-infected populations,[25, 26] no prior study has specified psychiatric comorbidity in a 
sample of HIV-infected patients with a confirmed diagnosis of MDD, nor whether this 
comorbidity is associated with greater illness severity. In this paper, our team assesses the 
prevalence and correlates of psychiatric comorbidity among a population of HIV-infected 
patients with confirmed MDD who enrolled in a depression treatment study. We examine 
the extent to which depression treatment interventions for HIV-infected individuals needs to 
consider psychiatric comorbidity for maximal reach and effectiveness. Accordingly, our 
goals for this paper are 1) to describe the prevalence of comorbid psychiatric disorders in 
persons with MDD enrolling in a depression treatment study in a representative sample of 
HIV outpatients, and 2) to identify sociodemographic and clinical/behavioral features 
associated with the number and type of concurrent psychiatric conditions.
1.2 MATERIALS AND METHODS
1.2.1 Study Design/setting
SLAM DUNC was a randomized controlled effectiveness trial implemented at the infectious 
diseases clinics at 3 academic medical centers: Duke University (lead site; Clinic 2J), the 
University of North Carolina at Chapel Hill (UNC Infectious Diseases Clinic), and the 
University of Alabama at Birmingham (1917 Clinic).[27] It was designed to test whether 
evidence-based decision support for antidepressant management, when integrated into HIV 
care, would improve HIV medication adherence and clinical outcomes (ClinicalTrials.gov 
registry # NCT01372605). Eligible and consenting participants were randomized to one of 
two conditions: Measurement-Based Care (MBC, hereafter referred to as “intervention”) or 
enhanced treatment as usual (hereafter referred to as “usual care”). No advertisements for 
clinical trial participants were conducted; all potential participants were already patients in 
the respective clinics.
1.2.2 Study population
Patients seeking care at participating sites were eligible if they were HIV-infected, ages 
18-65 years old, English-speaking, prescribed or about to start any FDA-approved 
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antiretroviral medication, scored 10 or higher on the Patient Health Questionnaire-9 
depression screener [28], and subsequently had a current major depressive disorder 
diagnosis confirmed by the Mini International Neuropsychiatric Interview (MINI), a 
commonly used short structured diagnostic interview with excellent reliability and good-to-
very good convergent validity relative to other gold standards for a variety diagnoses.
[29-31] Patients were excluded if they had a history or a current diagnosis of either a bipolar 
spectrum disorder (n=34) or a psychotic disorder or psychotic symptoms (n=19) as 
diagnosed by the MINI; were currently suicidal or had a substance use disorder requiring 
immediate inpatient treatment (n=1); or failed to respond to adequate trials of ≥2 different 
antidepressants during the current depressive episode (n=2). Written informed consent was 
obtained from each participant and all study activities were approved by the Institutional 
Review Boards at Duke University, the University of North Carolina at Chapel Hill, and the 
University of Alabama at Birmingham.
1.2.3 Assessment of Psychiatric Comorbidity
All diagnoses were based on DSM-IV-TR criteria.[32] At the time of enrollment, patients 
were evaluated for dysthymia (a chronic, low grade depressive illness now referred to as 
persistent depressive disorder in the DSM-V[33]), panic disorder, generalized anxiety 
disorder (GAD), posttraumatic stress disorder (PTSD), alcohol dependence/abuse, and 
substance dependence/abuse, using the relevant subsections of the MINI.
1.2.4 Associated baseline variables of interest
We collected standard sociodemographic measures as well as clinical and behavioral 
measures thought to be relevant to psychiatric comorbidities. Specifically, we assessed 
adherence, using a baseline self-report along a visual analog scale from 0-100% of how 
much of the time the participant took all of the prescribed HIV/AIDS medicines over the 
prior month;[34] a self-report of 12 potential HIV-related symptoms over the prior 6 months 
(headaches; fever, sweats or chills; pain in the mouth; white patches in the mouth; painful 
rashes or sores; nausea or loss of appetite; eye trouble; sinus infection; numbness in hands or 
feet; persistent cough; diarrhea);[35] a self-report measure of sexual behaviors, including 
unprotected sex, over the prior 3 months; a measure of health-related quality of life using the 
Short Form 12 (SF-12),[36] which has a general population mean of 50 for physical and 
mental health subscores and for which higher scores indicate better quality of life; 
suicidality over the past week, as indicated on the Hamilton Rating Scale for Depression-17 
item version (HRSD)[37]; detectable viral load (HIV RNA VL >48 copies/mL); and self-
report of hospitalization and emergency department use over the prior 3 months.
1.2.5 Data Analysis
Data are presented as means (standard deviations) or percentages. Chi-square tests, t-tests, 
and ANOVA were used to compare categorical and continuous characteristics and outcomes 
(a) between those with no vs. one or more comorbidities, and (b) between those with 
depressive disorders only (depression with or without dysthymia) vs. those with comorbid 
anxiety disorders (but no substance use) or vs. those with comorbid substance use disorders 
(with or without anxiety disorders). We used multiple linear and logistic regression to 
estimate the independent associations of dysthymic, anxiety, and substance use disorders 
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with a range of behavioral and health outcomes, with all models adjusted for covariates 
determined to be important a priori (age, gender, and employment status). A p-value of 
<0.05 was considered statistically significant; a p-value between 0.05 and 0.10 was 
considered a trend. No adjustments of P-values for multiple comparisons were performed 
given the exploratory nature of this report.
1.3 RESULTS
1.3.1 Sample description
The SLAM-DUNC study enrolled 304 participants (Table 1). The mean age of those 
participating was 44 years, and 71% were male. The sample averaged 13 years of completed 
education. Sixty-two percent of those enrolled were black, 51% were single or never 
married, and 73% were unemployed. On average, participants had been diagnosed with HIV 
for 11 years.
Self-reported adherence to ART was high, with a mean self-reported adherence of 87%. The 
mean number of reported HIV symptoms was 5.1. Both mental functioning (mean SF-12 
Mental Health Composite Score = 30) and physical functioning (mean SF-12 Physical 
Composite Score = 44) suggested below average health-related quality of life. Thirty-three 
percent of participants had a detectable viral load (>48 copies/mL), and 18% reported 
having had unprotected sex in the past 3 months.
1.3.2 Prevalence of comorbid disorders
All participants had complete comorbidity information. Complicated depressive illness was 
common. Most MDD (59%) was recurrent (Table 1). Only 18% (4% single episode, 14% 
recurrent) were experiencing MDD with no comorbid psychiatric diagnoses (Figure 1). 
Chronic depression was common, with 49% of MDD patients having a concurrent 
dysthymic disorder (Table 2). Comorbid anxiety disorder was present in 62%, most 
commonly GAD (48%), followed by PTSD (22%) and Panic Disorder (14%). A comorbid 
substance use disorder existed in 28%, with the prevalence of dependence on alcohol or 
drugs (15-16%) being more common than abuse (3-5%). Of all participants, 30% had one 
comorbid diagnosis besides MDD, 28% had 2 concurrent diagnoses, and 25% had 3 or more 
comorbidities.
1.3.4 Clinical and sociodemographic features associated with various 
degrees of comorbidity
There was little difference in baseline sociodemographic variables between those with no 
comorbidities and those with 1 or more (Table 3). The comorbid group did not differ from 
the MDD alone group by age, sex, race, income level, time since diagnosis, or education. 
However those with any comorbidity were significantly more likely to be unemployed (76% 
vs. 59%, p=0.01). Compared to those with only depression and/or dysthymia, the likelihood 
of unemployment was higher among those with anxiety disorders (79% vs. 62%, p=0.01) 
and showed a trend toward being higher among those with substance use disorders (75% vs. 
62%, p=0.08).
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Comorbidity, in general, was associated with greater disease severity. Of note, this 
association was not observed in self-reported adherence or HIV viral load suppression at 
baseline, which did not vary between groups (Table 3). However, psychiatric comorbidity 
was associated with greater HIV symptom severity. Compared to those with MDD alone, the 
comorbid group reported more mean HIV symptoms (5.1 vs. 4.1, p=0.01) and tended to 
report worse physical functioning on the SF-12 (43 vs. 47, p=0.08). Also, the comorbid 
group reported lower overall mental health functioning (p<0.01). Compared to those with 
depressive or dysthymic disorders alone, mental health functioning was lower among those 
with anxiety disorders (mean=28 vs. 33, p<0.01) but was not statistically significantly 
different among those with substance use disorders (31 vs. 33, p=0.14).
Finally, we used multivariable regression models to assess whether there were independent 
associations between the specific types of psychiatric comorbidity and HIV behavioral and 
health outcomes (Table 4). Having a comorbid dysthymic disorder was significantly 
associated with worse mental functioning and nearly twice the likelihood of suicidality 
within the past week. Further, there was a trend towards a greater likelihood of an 
emergency department visit for this population (p<0.10). Having a comorbid anxiety 
disorder was significantly associated with a greater number of reported HIV symptoms and 
worse mental health functioning, but no clear association with increased suicidality or 
increased emergency department use. There was a trend towards worse physical functioning 
(p<0.10) for those with a comorbid anxiety disorder.
Substance use comorbid with depression was associated with a trend towards greater odds of 
having a detectable viral load and greater odds of unprotected sex in the previous 3 months 
(p<0.10)
1.4 DISCUSSION
In the only study to date that provides a diagnostic assessment of psychiatric comorbidity in 
a sample of HIV patients with MDD receiving ART, we found that having a comorbid 
psychiatric illness is the norm. Nearly half of study participants had a comorbid dysthymic 
disorder, a chronic depressive illness distinct from MDD that is an independent risk factor 
for treatment-resistant depression.[38] Even when one excludes dysthymia, three quarters of 
depressed patients had a comorbid anxiety and/or substance use disorder. Thus, in this 
patient population of HIV-infected individuals selected as reasonable candidates for a 
depression treatment study, the prevalence of comorbid psychiatric disorders likely to 
complicate the depression treatment course was high.
Prior assessments of psychiatric comorbidity have been limited and primarily based on 
either retrospective chart reviews of diagnoses.[39] or by positive psychiatric screens (rather 
than diagnostic assessments),[40] which can overstate prevalence rates by as much as 16% 
in this population. [41, 42] One exception carefully assessed multiple psychiatric diagnoses 
using the Structured Clinical Interview for DSM-IV on a convenience sample of 66 patients 
who had screened positive for depression, but this study did not characterize psychiatric 
comorbidity in those specifically with MDD.[43] Further, their sample differed by including 
depressed patients with psychotic symptoms or bipolar spectrum illness, which our selection 
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criteria excluded, and by assessing for dysthymia. Their findings showed MDD-only 
diagnosis in 4% of the screen positive sample, and they reported the same proportion (62%) 
had anxiety comorbid with MDD. However, twice as many in their sample were diagnosed 
with comorbid anxiety, depressive, and substance use disorders (30% vs. 14% prevalence). 
Further, specific types of comorbidity differed. We identified 22% with comorbid PTSD, 
compared to 10% in their population of those with screen-positive depression. These 
differences are likely related to the dissimilar populations sampled, but underscore the 
complexity of comorbid psychiatric presentations in HIV clinical settings.
In our study, psychiatric comorbidity was associated with greater HIV disease severity and 
worse quality of life, reflected in greater HIV symptomatology and worse physical and 
mental health functioning. For example, those with comorbid dysthymia were nearly twice 
as likely to have suicidal thoughts in the past week, suggesting a greater need for more 
frequent and closer monitoring of psychological status. Having a comorbid substance use 
disorder was associated with nearly twice the likelihood of having a detectable viral load 
while on ART, suggesting a greater need for more frequent and closer monitoring of a 
patient's HIV treatment response. Having both comorbidities (12% of our sample) might 
suggest the need to monitor both psychiatric and HIV clinical status more closely. In any 
case, the frequency and associated effects of these comorbidities suggest the need for more 
comprehensive treatment plans for patients presenting to the HIV clinic with MDD.
Our study has limitations. It is cross-sectional and so can only assess associations, not causal 
relationships. However, these results underscore the complexity of HIV-infected patients 
presenting with depression and identify psychiatric comorbidity as a potential key 
confounder of the association between depression and adverse HIV outcomes. Also, our 
findings apply only to those with MDD, and are not applicable to patients with psychotic or 
bipolar disorders. Such a focus, however, is likely more representative of patients whose 
mental health might be managed in an outpatient HIV clinic, as those with psychotic or 
bipolar spectrum presentations more often would be referred to a mental health professional. 
Finally, our study is exploratory in nature and a first step towards better understanding this 
comorbidity; larger studies are necessary to confirm these findings.
For HIV patients with major depression, psychiatric comorbidity and chronic depression are 
strikingly common rather than the exception, and this complexity is associated with greater 
HIV disease severity and worse prevention and treatment indicators. An appreciation of this 
comorbidity can help clinicians better target those at risk of harder-to-treat HIV disease, and 
it underscores the challenge of treating depression in this population.
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Table 1
Description of sample (n=304).




        Male 215 (71%)
        Female 89 (29%)
Race
        White non-Hispanic 93 (31%)
        Black non-Hispanic 188 (62%)
        Hispanic 9 (3%)
        Other 14 (5%)
Income (monthly), $ $1,534 (2,887)
Marital Status
        Married/co-habitating 68 (23%)
        Separated, divorced, widowed 78 (26%)
        Single/never married 155 (51%)
Employment Status
        Employed 81 (27%)
        Unemployed 219 (73%)
Time since diagnosis (years) 11 (8)
Education (years completed) 13 (3)
Past depressive episodes
        None 124 (41%)
        ≥1 180 (59%)
Behavioral and Health Measures -
Self-reported adherence, past month 87 (23)
Number HIV symptoms, past 6 months 5.1 (3.0)
SF-12 mental functioning 30 (10)
SF-12 physical functioning 44 (12)
HIV RNA VL >48 copies/mL 101 (33%)
Any unprotected sex, past 3 months 56 (18%)
Any unprotected sex with HIV- or status-unknown partner 25 (8%)
Any suicidality, past week 91 (30%)
Any hospitalization, past 3 months 20 (7%)
Any emergency department visit, past 3 months 74 (25%)
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Table 2
Prevalence of psychiatric comorbidities at baseline among SLAM DUNC study participants.
Diagnosis n %
Dysthymia 148 49%
Any anxiety disorder 187 62%
        Panic disorder, current 43 14%
        PTSD, current 65 22%
        GAD 144 48%
Any substance use disorder 85 28%
        Alcohol abuse (no dependence) 14 5%
        Alcohol dependence 44 15%
        Drug abuse (no dependence) 8 3%
        Drug dependence 47 16%
Number of comorbid diagnoses
*
        0 54 18%
        1 90 30%
        2 85 28%
        3 or more 75 25%
*
In addition to MDD
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Table 3
Demographic, behavioral, and health correlates of comorbidity
Number of comorbidities Type of comorbidity*
None 1 or more P Value None or dysthymia Anxiety 
but no SA P value
* Substance use P Value
***
n 54 (18%) 250 (82%) 83 (27%) 136 (45%) 85 (28%)
Age, years 44 (11) 44 (10) 0.84 44 (11) 45 (9) 0.44 43 (11) 0.55
Sex
Male 35 (65%) 180 (72%) 0.29 59 (71%) 87 (64%) 0.28 69 (81%) 0.13
Female 19 (35%) 70 (28%) 24 (29%) 49 (36%) 16 (19%)
Race
White non-Hispanic 12 (22%) 80 (32%) 0.24 21 (25%) 48 (35%) 0.05 24 (28%) 0.65
Black non-Hispanic 38 (70%) 150 (60%) 55 (66%) 81 (60%) 52 (61%)
Hispanic 1 (2%) 12 (5%) 2 (2%) 6 (4%) 5 (6%)
Other 3 (6%) 7 (3%) 5 (6%) 1 (1%) 4 (5%)
Income, log (10) 2.7 (1.1) 2.7 (1.0) 0.98 2.7 (1.1) 2.7 (1.0) 0.97 2.7 (1.0) 0.89
Marital Status
Married/co-habitating 10 (19%) 58 (23%) 0.73 16 (19%) 37 (27%) 0.28 15 (18%) 0.95
Separated, divorced, widowed 15 (28%) 63 (26%) 21 (25%) 37 (27%) 20 (24%)
Single/never married 29 (54%) 126 (51%) 46 (55%) 61 (45%) 48 (58%)
Employment Status
Employed 21 (41%) 59 (24%) 0.01 31 (38%) 29 (21%) 0.01 21 (25%) 0.08
Unemployed 32 (59%) 187 (76%) 51 (62%) 106 (79%) 62 (75%)
Time since diagnosis (years) 12 (10) 11 (8) 0.50 11 (9) 12 (8) 0.78 10 (8) 0.56
Education (years completed) 14 (4) 13 (2) 0.48 13 (4) 13 (2) 0.83 13 (3) 0.42
Self-reported adherence, past 
month
86% (24%) 87% (22%) 0.83 84% (27%) 88% (21%) 0.24 86% (19%) 0.76
Number of HIV symptoms, 
past 6 months
4.1 (3.0) 5.1 (2.9) 0.01 4.2 (3.0) 5.4 (2.9) 0.01 5.6 (2.8) 0.00
SF-12 MCS Score 35 (13) 29 (9) 0.00 33 (12) 28 (8) 0.00 31 (9) 0.14
SF-12 PCS Score 47 (13) 43 (12) 0.08 46 (13) 42 (11) 0.01 46 (12) 0.97
Self-reported adherence 
>=80%, past month
41 (84%) 185 (81%) 0.68 64 (82%) 104 (85%) 0.64 48 (76%) 0.38
HIV RNA VL >48 copies/mL 16 (31%) 74 (33%) 0.85 23 (31%) 35 (28%) 0.69 32 (42%) 0.16
Any unprotected sex, past 3 
months
10 (20%) 46 (21%) 0.94 15 (19%) 21 (17%) 0.65 20 (29%) 0.16
Any unprotected sex with 
HIV-or status-unknown 
partner
5 (10%) 20 (9%) 0.81 7 (9%) 11 (9%) 0.96 7 (10%) 0.81
Any suicidality, past week 12 (24%) 79 (36%) 0.10 22 (28%) 46 (38%) 0.17 23 (34%) 0.46
Any hospitalization, past 3 
months
3 (6%) 17 (7%) 0.72 3 (4%) 10 (7%) 0.25 7 (9%) 0.19
Any emergency department 
visit, past 3 months
13 (24%) 61 (25%) 0.91 23 (28%) 35 (26%) 0.77 16 (20%) 0.22
All statistics presented as mean (SD) or n (%).
Substance use: Alcohol or substance abuse or dependence, with/without anxiety disorders.
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*
P value comparing None or dysthymia to Anxiety but no SA
***
P value comparing None or dysthymia to Substance use
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Table 4
Independent associations of dysthymia, anxiety, and substance use comorbidity with HIV behavioral and 
health outcomes
Dysthymia Anxiety Substance use
        Mean difference (95% CI)
Number of HIV symptoms, past 6 months 0.54 (−0.14, 1.23) 0.73 (0.02, 1.44)
^ 0.61 (−0.15, 1.38)
SF-12 mental functioning −2.77 (−5.01, −0.52)
^
−3.89 (−6.18, −1.59)
^ 0.51 (−1.97, 2.99)
SF-12 physical functioning −2.57 (−5.31, 0.17) −1.78 (−4.59, 1.03) 2.45 (−0.57, 5.48)
Self-reported adherence, past month 0.81 (−4.69, 6.31) 4.49 (−1.12, 10.09) −1.28 (−7.37, 4.82)
        Odds ratio (95% CI)
HIV RNA VL >48 copies/mL 1.16 (0.69, 1.95) 0.90 (0.52, 1.53) 1.65 (0.95, 2.86)
Any unprotected sex, past 3 months 1.39 (0.76, 2.54) 0.79 (0.43, 1.54) 1.87 (0.98, 3.54)
Any unprotected sex with HIV- or status-unknown partner 0.68 (0.29, 1.58) 1.00 (0.43, 2.33) 1.23 (0.49, 3.12)
Any suicidality, past week 1.98 (1.17, 3.35)
^ 1.22 (0.71, 2.09) 0.89 (0.49, 1.62)
Any hospitalization, past 3 months 1.39 (0.54, 3.57) 2.56 (0.82, 7.97) 1.48 (0.56, 3.90)
Any emergency department visit, past 3 months 1.63 (0.95, 2.80) 0.82 (0.47, 1.42) 0.64 (0.34, 1.20)
* From ordinary least squares or logistic regression models, adjusted for age, gender, and employment status.
^
p < 0.05
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